RecruitingNCT06227728

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.

Sponsor

Gene Solutions

Enrollment

50 participants

Start Date

Mar 22, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Liver Cancer Colorectal, Cancer Gastric Cancer Non-small Cell Lung Cancer Advanced Cancer Immune Checkpoint Inhibitor

Summary

This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tumor and blood samples from patients with stage IV (metastatic) cancer who are about to start immunotherapy. The goal is to understand which biological markers predict who will respond to immunotherapy and how well. **You may be eligible if...** - You are 18 or older with confirmed stage IV cancer (such as lung, colon, breast, liver, or stomach cancer) - You are about to start immunotherapy (immune checkpoint inhibitors) as your first or second treatment line - Tumor tissue from a biopsy or surgery is available - You have not yet started immunotherapy or chemotherapy **You may NOT be eligible if...** - You have already started immunotherapy or chemotherapy before enrolling - You are receiving a specific type of immunotherapy called consolidation therapy (e.g., durvalumab after radiation) - You have medical or psychiatric conditions that prevent you from following the study protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

University of Medicine and Pharmacy at HCMC

Ho Chi Minh City, Hồ Chí Minh, Vietnam

Medical Genetics Institute

Ho Chi Minh City, Vietnam

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06227728

Related Trials

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760229 locations

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT052868141 location

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT072146624 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT058799261238 locations